To view this email as a web page, click here

Today's Rundown

Featured Story

Galapagos' osteoarthritis drug flunks phase 2, dashing hopes of $250M Gilead deal

Galapagos and Servier’s GLPG1972 has failed to improve outcomes in knee osteoarthritis patients in a phase 2 clinical trial. The failure of the ADAMTS-5 inhibitor is a setback for Galapagos’ efforts to expand its opportunities beyond its faltering JAK1 inhibitor filgotinib.

read more

Top Stories

Eli Lilly strikes deal to sell R&D campus to UCB

Eli Lilly has struck a deal to sell a U.K. R&D campus to UCB. The deal positions UCB to turn the former Lilly neuroscience center into one of its three global R&D hubs.

read more

Hey, biopharma: JPM isn't the be-all, end-all for dealmaking, Sanofi exec says

Among the many things we took for granted before COVID-19 were in-person gatherings, where everyone in biopharma could catch up, talk shop and maybe emerge with a new partner or two. Sanofi isn’t sweating it, though—the sudden need to go virtual gave companies a chance to get out of their dealmaking comfort zone.

read more

Aligos, Tarsus bank $238M as biotech IPO party continues

Let’s add two more to the list—a pair of clinical-stage biotechs collectively raised more than $200 million in their Nasdaq debuts. Hepatitis B and COVID-19-focused Aligos Therapeutics raised $150 million, while eye disease player Tarsus Pharmaceuticals reeled in $88 million.

read more

Praxis clinches $190M IPO, surpassing even its upsized target

2020 is turning out to be a big year for Praxis Precision Medicines. After launching in May with $100 million, the CNS-focused biotech wasted no time topping up its coffers with another $110 million. Now, it’s closed a $190 million IPO, upgrading from the $100 million listing it originally sought in September.

read more

Insilico, Taisho form AI partnership to tackle age-related diseases and mortal cells

Taisho Pharmaceutical tapped AI drug discovery maven Insilico Medicine to identify new therapeutic compounds that could slow the cellular effects of aging, with the ultimate goal of helping people stay healthy as they grow older.

read more

Pfizer CEO, facing pushback, shifts COVID vaccine timeline to late November

Pfizer CEO Albert Bourla recently suggested the company would know whether its BioNTech-shared COVID-19 vaccine works by October. Criticism ensued. Now finding himself alone in the biopharma world with that bullish estimate, the Big Pharma chief is changing his tone.

read more

FiercePharmaAsia—COVID-19 drug manufacturing; Roche's China slowdown; Astellas' Iota buy

Takeda and CSL are scaling up manufacturing of their COVID-19 hyperimmune immunoglobulin drug. Eli Lilly has tapped Fujifilm to help handle production of its coroavirus antibody candidate. Roche's China business suffered amid pandemic hospital constraint and oncology price cuts. Astellas acquires bioelectronics maker Iota Biosciences. And more.

read more

Chutes & Ladders—Biogen veteran Ong joins Flagship Pioneering as CEO-partner

Flagship Pioneering adds Ong as CEO-partner; Touchlight taps Lonza vet Fallen as business unit CEO; Dewpoint taps Nathwani as CEO.

read more

Resources

Whitepaper: COVID-19 Vaccine Clinical Trials in Children: Challenges on the Horizon

Understanding the Challenges COVID-19 Pediatric Clinical Trials Face | White Paper

Whitepaper: Exploring the patient dynamic from different perspectives

The culture of clinical research is evolving from one directed by researchers to one driven by the needs of patients and those who care for them.

Whitepaper: High Content Screening in 3D: Faster 3D Image & Multi-Parametric Data Analysis

Creating integrated HCS workflows in a single platform increases accuracy; reduces time and helps to identify the most appropriate hits or drug candidates. Learn more about a reliable method for creating a more efficient, faster, 3D image and multi-parametric data analysis workflow.

eBrief: Drug Product Process Development: Ensuring a Consistent, High-quality Biologic

Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase.

Whitepaper: Go from Process R&D to Clinical APIs Quickly and Effectively

Struggling with complex chemistry to get APIs for clinical trials? Find out what to look for in an API CDMO partner to gain expertise and speed that lead to success.

Whitepaper: COMPLIANCE –THE COMPETITIVE DIFFERENTIATOR TO COMMERCIALIZATION: An Integrated Model Setting the New Global Standard

An integrated compliance model can be the competitive differentiator to commercialization and move the needle from cost center to value. Learn How.

Q&A: Planning Successful Launches

Learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools.

eBook: CMC Considerations for Successful Early Drug Development

This eBook provides insights on key approaches and considerations for preparing your drug development program for long-term success.

Webinar: Phase Appropriate Expertise and Technologies to Accelerate Product Development to Commercialization

In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site.

Whitepaper: How to Achieve Time and Cost Reductions in Clinical Trial Design and Build

Learn how to save time and reduce costs and complexity by streamlining the clinical trial process.

Whitepaper: Position Your Pharmaceutical Lab for Success

Want to leapfrog lengthy LIMS deployments and position your pharmaceutical lab for success? Find out how with LabVantage Solutions.

Whitepaper: Technology Transfers: Reaping Rewards, Reducing Risks

Learn how to safeguard supply, improve distribution and reduce program costs and risks

Whitepaper: Making Data Central to Your CNS and Pain Trials

Learn how the right data capture solution can prompt the patient to follow the correct procedures and automatically sort the responses, according to protocol.

Whitepaper: Research Reveals New Launch Standards for First-to-launch Pharma and Biotech Companies

While COVID-19 has shifted the rules of the healthcare industry, research shows there was already progress on changes being made for how pharma companies are launching products.

Whitepaper: 16 Biopharma Leaders Tell How COVID-19 Will Change Customer Engagement

Senior executives from 16 biopharma companies share their thoughts on how COVID-19 will change how the industry engages with its customers.

A complete Life Science Industry Snapshot in One Report

Whitepaper: Five Imperatives for Becoming More Patient-Centric

Achieving patient centricity depends on evolving how evidence is generated.

Whitepaper: Why Your Business Needs a Ransomware Strategy To Avoid Being Hacked!

Cybercriminals Are Actively Exploiting The Coronavirus Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become The Next Ransomware Headline -- Make These Changes Now!

Whitepaper: Leverage Technology to Expedite Master Protocol Trials

This white paper addresses the complexity of basket and umbrella designs, and how modern technology is critical to run flexible, agile and quality-driven trials.

Whitepaper: Achieving a Successful Drug Product Technology Transfer

Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent.

Executive Summary: Keys to a Successful Rapid Commercial Launch

Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better.

Whitepaper: The Art of Recognizing Clinical Supply Risk Factors

In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management.

Case Study: Establishing Parameters for Success

Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study.

Fact Sheet: Forecasting to Optimize Clinical Trial Supply Management

Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study.

eBook: Expecting the Unexpected: Strategies for Efficient Clinical Supply Management and Forecasting

Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study.

Events